Friday, 16 October 2026European Markets

ABC ARBITRAGE And BOURSE DIRECT Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - abc arbitrage (abca.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
abc arbitrage (abca.pa) €3.95 9.34% 13.59%
bourse direct (bsd.pa) €4.75 1.7% 14.89%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. abc arbitrage (abca.pa)

9.34% forward dividend yield and 13.59% return on equity

abc arbitrage sa, together with its subsidiaries, engages in the development of arbitrage strategies for liquid assets worldwide. it develops liquidity, statistical, risk, and derivatives arbitrage strategies; and provides asset and portfolio management services. the company was incorporated in 1995 and is based in paris, france.

earnings per share

as for profitability, abc arbitrage has a trailing twelve months eps of €0.37.

pe ratio

abc arbitrage has a trailing twelve months price to earnings ratio of 10.68. meaning, the purchaser of the share is investing €10.68 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.59%.

more news about abc arbitrage.

2. bourse direct (bsd.pa)

1.7% forward dividend yield and 14.89% return on equity

bourse direct sa provides internet stock brokerage services in france. it offers a platform of services, tools, and financial products, including french and foreign equities, derivatives, trackers, warrants, certificates, turbos, mutual funds, ucits, and cfds, as well as tax exemption, retirement, real estate, and life insurance products through the boursedirect.fr, capitol.fr, tradebox.fr, abssysteme.fr, wargny.com, and mesactions.com sites. the company was founded in 1996 and is headquartered in paris, france. bourse direct sa is a subsidiary of e-viel sa. bourse direct et bourse discount sa provides french and foreign equities, derivatives, trackers, warrants, certificates, turbos, ucits, cfds, tax exemption products, real estate products, and direct horizon stock exchange life insurance contracts. the company was was incorporated in 1996 and is based in paris, france.

earnings per share

as for profitability, bourse direct has a trailing twelve months eps of €0.18.

pe ratio

bourse direct has a trailing twelve months price to earnings ratio of 26.39. meaning, the purchaser of the share is investing €26.39 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.89%.

volume

today's last reported volume for bourse direct is 14747 which is 58.96% above its average volume of 9277.

more news about bourse direct.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com